Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07313462
Recruiting Observational

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

NCT07313462 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2025-02-07
Last updated
2026-01-02

Condition(s) studied

Multiple Sclerosis (MS)

Study summary

The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with RRMS onset after age 50 * Patients who started their first disease-modifying therapy within 2 years of the first symptoms * Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon) * Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine) Exclusion Criteria: \- Patients with early progressive MS

Primary outcome measure(s)

  • Time to First Clinical Inflammatory Relapse — Up to 12 months
    Compare the time to first clinical inflammatory relapse between two groups of patients who developed relapsing-remitting MS (RRMS) after age 50: * Group 1 = therapeutic escalation strategy: starting with a moderately effective treatment (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon) * Group 2 = induction strategy: starting with a highly effective treatment (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

Trial sites (1)

FacilityCityRegionStatus
Centre d'Investigation Clinique - CHU de Strasbourg - France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

Phenotyping of Patients With Polycystic Ovary Syndrome Recruiting
Qualitative Study Exploring the Determinants Involved in the Management of Osteoporosis in Frail Elderly People Recruiting
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies Recruiting
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France Recruiting
Impact of an Information Sheet Given to Parents After an Initial Consultation for a Simple Febrile Seizure at Strasbourg University Hospital Recruiting

Other trials for the same condition

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France Active, not recruiting
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis Recruiting
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07313462 on ClinicalTrials.gov ↗ ← All trials in France